EU Safety Updates For Lenalidomide, Pegfilgrastim & Pembrolizumab
Executive Summary
The labeling of several major medicines marketed in the EU is to be updated to reflect cases of serious adverse events. The European Medicines Agency’s pharmacovigilance committee has also recommended a new warning on drug-drug interactions, and asked for additional information on several other products.
You may also be interested in...
Pfizer’s Dacomitinib And More Biosimilar Hopefuls Among New EMA Filings
There are eight new entries to the list of marketing applications filed with the European Medicines Agency, including submissions for more versions of Amgen’s Neulasta (pegfilgrastim), and a second biosimilar of Roche’s Avastin (bevacizumab).
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.